Table 2. Trial characteristics.
| Patients (%)/Trials | |
|---|---|
| Cytotoxic Combination Trials (N=7) | |
| Cytotoxic Agents | |
| Platinum + Taxane | 28 (41.8) / 1 |
| Cyclophosphamide | 19 (28.4) / 3 |
| Taxane | 20 (33.3) / 3 |
| Molecularly Targeted Agent Trials (N=8) | |
| MTA Pathways | |
| HER Inhibitor | 27 (45.0) / 2 |
| Notch Inhibitor | 4 (6.7) / 1 |
| ATR Inhibitor | 2 (3.3) / 1 |
| PI3 Kinase Inhibitor | 3 (5.0) / 1 |
| PARP Inhibitor | 13 (21.6) / 1 |
| CYP17A1 Inhibitor | 9 (15.0) / 1 |
| FGFR4 Inhibitor | 2 (3.3) / 1 |
Characteristics of trials in which the 127 patients analysed in this study were enrolled onto and participated in, with specific divisions the type of cytotoxic agent used and the pathways of the molecularly targeted agents.